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1 
Abstract 
 
Antony J Workman, Kathleen A Kane, Andrew C Rankin. Characterisation of the Na, K pump 
current in atrial cells from patients with and without chronic atrial fibrillation. 
Objective: To assess the contribution of the Na, K pump current (Ip) to the action potential duration (APD) 
and effective refractory period (ERP) in human atrial cells, and to investigate whether Ip contributes to the 
changes in APD and ERP associated with chronic atrial fibrillation (AF). Methods: Action potentials and 
ion currents were recorded by whole-cell patch clamp in atrial myocytes isolated from consenting patients 
undergoing cardiac surgery, who were in sinus rhythm (SR) or AF (>3 months). Results: In cells from 
patients in SR, the Ip blocker, ouabain (10 µM) significantly depolarised the membrane potential, Vm, from -
80±2 (mean±SE) to -73±2 mV, and lengthened both the APD (174±17 vs 197±23 ms at 90% repolarisation) 
and ERP (198±22 vs 266±14 ms; P<0.05 for each, Student’s t-test, n=7 cells, 5 patients). With an elevated 
pipette [Na
+
] of 30 mM, Ip was measured by increasing extracellular [K
+
] ([K
+
]o) from 0 to 5.4 mM. This 
produced an outward shift in holding current at -40 mV, abolished by 10 µM ouabain. K
+
- and ouabain-
sensitive current densities were similar, at 0.99±0.13 and 1.12±0.11 pA/pF, respectively (P>0.05; n=9 cells), 
confirming the K
+
-induced current as Ip. Ip increased linearly with increasing Vm between -120 and +60 mV 
(n=25 cells). Stepwise increments in [K
+
]o (between 0 and 10 mM) increased Ip in a concentration-dependent 
manner (maximum response, Emax=1.19±0.09 pA/pF; EC50=1.71±0.15 mM; n=27 cells, 9 patients). In cells 
from patients in AF, the sensitivity of Ip to both Vm and [K
+
]o (Emax=1.02±0.05 pA/pF, EC50=1.54±0.11 mM; 
n=44 cells, 9 patients) was not significantly different from that in cells from patients in SR. Within the group 
of patients in AF, long-term digoxin therapy (n=5 patients) was associated with a small, but significant, 
reduction in Emax (0.92±0.07 pA/pF) and EC50 (1.35±0.15 mM) compared with non-treatment 
(Emax=1.13±0.08 pA/pF, EC50=1.76±0.14 mM; P<0.05 for each, n=4 patients). In cells from non-digoxin-
treated patients in AF, the voltage- and [K
+
]o-sensitivity (Emax and EC50) were similar to those in cells from 
patients in SR. Conclusions: The Na, K pump current contributes to the human atrial cell Vm, action 
potential shape and ERP. However, the similarity in Ip sensitivity to both [K
+
]o and Vm between atrial cells 
from patients with and without chronic AF indicates that Ip is not involved in AF-induced 
electrophysiological remodelling in patients. 
Keywords: Na/K-pump; Membrane currents; Atrial function; Arrhythmia (mechanisms); Remodelling.
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Introduction  
 The Na, K pump (Na, K-ATPase) functions to regulate the intracellular Na
+
 concentration, [Na
+
]i, by 
actively extruding 3 Na
+
 in exchange for 2 K
+
 [1]. Na, K-ATPase is therefore electrogenic, exerting an 
outward, hyperpolarising current, Ip, which is known to influence the resting potential, Vm and repolarisation 
[2]. The Na, K pump current has been measured directly in various cardiac tissues and myocytes isolated 
from sheep [3], guinea pigs [4], rabbits [5,6] and dogs [7]. However, despite its potential to influence, or be 
influenced by, cardiac arrhythmias, Ip has not yet been measured directly in cells or tissues from the human 
heart. 
 Chronic atrial fibrillation (AF) shortens the atrial action potential duration (APD) and effective 
refractory period (ERP), thus contributing to the stabilisation of the arrhythmia [8-13]. The pattern of 
changes in ionic currents responsible for this is not fully understood. The density of atrial L-type Ca
2+
 (ICaL) 
and transient outward K
+
 (ITO) currents is consistently and markedly reduced in AF or rapid atrial pacing, in 
dogs [10] and humans [11-13]. However, recent work from our laboratory in human atrial cells [12] suggests 
that the shortening of APD and ERP by chronic AF cannot be explained by changes in these currents alone, 
consistent with a mathematical model [14], and data on the main alternatives are presently either unavailable, 
or in some cases, conflicting [13]. 
 The involvement or otherwise of Ip or Na,K-ATPase in AF-induced atrial electrophysiological 
remodelling is presently unclear [13]. In sheep, short episodes of rapid atrial pacing increased the expression 
of atrial Na, K-ATPase [15], although there was no effect on its activity [16]. In the goat model of AF, 
treatment with the Ip blocker, digoxin, had either no effect on AF-induced changes in atrial ERP and AF 
inducibility [17], or delayed their reversal [18]. However, Ip was not measured directly in any of these 
studies, and has not yet, to our knowledge, been recorded in any model of rapid atrial pacing or AF. 
 It is conceivable that the shortening of atrial APD and ERP by chronic AF in humans might involve an 
increase in atrial Ip. The aim was to test this hypothesis, by: 1) assessing the contribution of Ip to human atrial 
cell APD and ERP; 2) measuring Ip directly in atrial cells from patients in sinus rhythm (SR) and AF; 3) 
comparing the density, voltage- and extracellular [K
+
] ([K
+
]o)-sensitivity of Ip between these patient groups.
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Methods 
 The tip of the right atrial appendage was obtained from 25 consenting patients undergoing cardiac 
surgery. Procedures approved by the institutional research ethics committee were followed. The investigation 
conforms with the principles outlined in the Declaration of Helsinki [19]. Atrial cells were isolated by 
enzymatic dissociation and mechanical disaggregation, using protease (Type XXIV, Sigma) and collagenase 
(Type 1, Worthington), as described in detail previously [12]. 
 Action potentials and ion currents were recorded using the whole cell patch clamp technique. 
Microelectrodes were pulled (Narishige PP-83) from filamented borosilicate glass tubes (Clark 
Electromedical) and heat polished to resistances of 3-7 MΩ. Cells were superfused at 35-37
o
C, at 1.5-2 
ml/min in a 200 µl perfusion chamber (RC-24E, Warner). An Axopatch-1D amplifier (Axon Instruments) 
and “WinWCP” software (donated by J Dempster, Strathclyde University) was used to stimulate and record 
electrical activity. Capacitative transients were compensated electronically prior to recording. Signals were 
low-pass filtered at 5 kHz and digitised (Digidata 1200 A-D converter, Axon) prior to storage on magnetic 
and compact discs. 
 Action potentials were recorded using an extracellular solution containing (mM): NaCl (130), KCl (4), 
CaCl2 (2), MgCl2 (1), glucose (10) and HEPES (10), and a pipette solution containing: K-aspartate (110), 
KCl (20), MgCl2 (1), EGTA (0.15), Na2ATP (4), Na2GTP (0.4) and HEPES (5). A liquid junction potential 
of +7±0.3 mV (n=6) was measured and compensated prior to seal formation. Action potentials were 
stimulated using 5 ms duration current pulses of 1.2x threshold strength, with an 8-pulse (S1) conditioning 
train (75 beats/min). All cells were current-clamped (with hyperpolarising current of <150 pA) initially to a 
maximum diastolic potential (MDP) of ~-80 mV (measured from the 7th S1 response) and the holding 
current was kept constant in each cell thereafter. The APD was calculated as the interval between the action 
potential upstroke and repolarisation to the level of 50, 75 and 90% (APD50, APD75 and APD90, respectively). 
Action potential restitution was measured by introducing a progressively premature test pulse (S2) after the 
S1 trains, with S1 and S2 of equal magnitude. From this, the cell’s ERP was measured, as previously [12,20], 
as the longest S1-S2 interval failing to elicit an S2 response of amplitude >80% [21] of the preceding S1 action 
potential. The action potential maximum upstroke velocity (Vmax) was measured by automatically scanning 
phase 0 at high time resolution for the maximum slope between two adjacent voltage samples. Action 
potentials were recorded before and after superfusion with ouabain (10 µM) for 120 s, and again following 
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its removal. This concentration was chosen to avoid “rundown” of currents during the experimental 
protocols, since complete Ip block by 1 µM ouabain required 6-10 min superfusion, whilst 10 µM ouabain 
required only 40-80 s (eg: see Fig 2).  
 Ip was recorded over a wide voltage range, using solutions selected to minimise contamination from 
other currents [4,6]. The extracellular solution contained (mM): NaCl (145), CsCl (2), MgCl2 (0.5), glucose 
(10), HEPES (5), NiCl2 (2), BaCl2 (1). Cs
+
 was used to block If, IK1 and IKACh; Ni
2+
 to block INa/Ca, and Ba
2+
 to 
block IKP [22]. [Ca
2+
]o was kept at zero to avoid ICaL. [K
+
]o was initially kept at zero to record currents in the 
absence of Ip, prior to its activation. INa was inactivated with a holding potential of -40 mV. The pipette 
solution contained (mM): Aspartic acid (100), CsCl (20), MgCl2 (2), HEPES (5), MgATP (5), EGTA (10), 
K-creatine phosphate (5), CsOH (90) and NaOH (30). K
+
 was replaced by Cs
+
 to block outward K
+
 currents. 
A high degree of intracellular [Ca
2+
] ([Ca
2+
]i)-buffering minimised Ca
2+
-activated currents, and high [Na
+
]i 
was used to record Ip at close to full saturation [4,6]. A liquid junction potential (+7±0 mV, n=3) was 
compensated. The holding current was measured before and after superfusion with 5.4 mM KCl, and 
following its removal. One or more of the following protocols was then performed. The sensitivity to a 
cardiac glycoside of the extracellular K
+
 (K
+
o)-induced holding current shift was investigated, using ouabain 
at 1 and 10 µM. The voltage-sensitivity of K
+
- and glycoside-sensitive currents was determined using voltage 
ramps (increasing from -120 to +60 mV, at 36 mV/s) or rectangular voltage pulses (300 ms duration, 
increasing from -120 to +60 mV, at 0.1 Hz). Finally, the sensitivity of the current shift to [K
+
]o was 
determined with stepwise-incrementing [K
+
]o between 0 and 10 mM. 
 Details of patients’ clinical characteristics and drug treatments were obtained from the case notes and 
stored in a database (Access, Microsoft). All currents were normalised to cell capacity. [K
+
]o-response data 
were fitted iteratively in each cell with variable slope sigmoidal curves (Prism, GraphPad). Values are cell 
means±SE. Differences between means were assessed using 2-tailed paired or unpaired Student's t tests, as 
appropriate. Differences between incidences of patients receiving specified drugs were compared using a χ
2
 
test. P<0.05 was regarded as statistically significant. 
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Results 
 
Patients’ clinical characteristics 
 The patients’ characteristics are shown in Table 1. The majority of patients underwent coronary artery 
bypass graft surgery (76%) and suffered from angina (84%). Of patients in AF at the time of surgery, only 
those in which AF had persisted for longer than 3 months were included. Half of these patients underwent 
mitral valve surgery, versus none of those in SR. The medication taken by the patients is detailed in Table 1 
and it is noteworthy that none of the patients in SR were taking digoxin, in contrast to 60% of patients in 
chronic AF. All patients on digoxin had been receiving the drug for longer than 2 months and patients 
received their routine cardiac drugs on the day of surgery. 
 
Effects of superfusion with ouabain on human atrial cell action potentials and refractoriness 
 The Ip blocker, ouabain (10 µM) significantly affected the single cell Vm, action potential shape and 
ERP, as shown in the representative recordings in Fig 1 and mean data in Table 2. Ouabain depolarised the 
MDP by ~7 mV (Fig 1A and Table 2), associated with a marked reduction in the action potential Vmax, 
overshoot and amplitude and a significant prolongation of early (APD50) and late (APD 75 and APD90) 
repolarisation. Fig 1B shows the action potential restitution characteristics and ERP measurement in the 
absence and presence of ouabain, in the same cell as Fig 1A. The ouabain-induced depolarisation was 
associated with slowing of the recovery of excitability, flattening of the restitution curve, and marked and 
significant lengthening of the cell ERP, from 198±22 to 266±14 ms (P<0.05; n=5 cells, 4 patients). 
 
Activation of human atrial Ip by physiological [K
+
]o was abolished by ouabain 
 The representative current trace shown in Fig 2A shows that, using an elevated pipette [Na
+
] of 30 mM, 
increasing [K
+
]o from 0 mM to the physiological value of 5.4 mM produced an outward shift in the holding 
current at -40 mV, of approximately 1 pA/pF. This response was complete after approximately 60 s of K
+
 
application, and was fully reversed after K
+
 removal. A second application of K
+
 produced a current shift of 
similar magnitude. This was abolished by superfusion with ouabain (10 µM), with a similar time course of 
effect as that caused by the prior removal of K
+
. The effect of 1 µM ouabain was also investigated for 
comparison, in a different cell (Fig 2B). The K
+
-induced outward current was again abolished by ouabain, 
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but with a substantially longer time course than at 10 µM. A comparison between the mean current shift 
produced by the increase in [K
+
]o and the reverse shift produced by ouabain, is shown in Fig 2C. The K
+
- and 
ouabain-sensitive current densities were similar, at 0.99±0.1 and 1.12±0.113 pA/pF (for 10 µM ouabain), 
respectively (P>0.05; n=9 cells, 3 patients), indicating that the K
+
-induced current was Ip. 
 
Human atrial Ip was voltage-dependent 
 The steady-state voltage-dependency of Ip was examined using rectangular voltage pulses, in cells 
from 9 patients in SR. Fig 3Ai shows representative currents recorded in the absence and presence of 5.4 
mM K
+
o. All cells displayed steady-state responses between -120 and +20 mV (Fig 3Ai). A small time-
dependent component was observed at +60 mV in 59% of cells, possibly reflecting incomplete K
+
 current 
suppression. The currents recorded prior to K
+
 application were digitally subtracted from those recorded in 
its presence, as shown in the bottom panel of Fig 3Ai. The subtraction currents were time-independent 
between -120 and +60 mV in all cells. The mean current-voltage (I-V) relationship of these currents, shown 
in Fig 3Aii, demonstrated that the K
+
o-sensitive current was voltage-dependent, increasing approximately 
linearly from 0.47±0.10 pA/pF at -120 mV to 1.36±0.22 pA/pF at +60 mV (P<0.05, n=17 cells). Voltage 
ramp pulses were also used, to examine and compare the pseudo-steady-state I-V relationships of both K
+
- 
and 10 µM ouabain-sensitive currents. Fig 3Bi shows the current responses to these ramps, prior to and 
following superfusion with 5.4 mM K
+
 and after its removal, with the K
+
-sensitive (subtraction) current in 
the lower panel. Mean I-V relationship data (Fig 3Bii), obtained in cells from 12 patients, confirmed that the 
voltage ramp-evoked K
+
o-sensitive current displayed a similar voltage-dependence to that of the steady-state 
current. The voltage-dependent characteristics of the ouabain-sensitive current (Fig 3C) were similar to those 
of both the steady-state (Fig 3A) and pseudo-steady-state (Fig 3B) currents, indicating that the voltage-
dependent characteristics of the K
+
o-evoked current were those of Ip. 
 
Ip was increased by K
+
o in a concentration-dependent manner 
 The amplitude of Ip increased in response to increasing [K
+
]o, as shown in Fig 4. Ip was measured from a 
holding potential of -40 mV, and [K
+
]o was increased in a stepwise manner between 0 and 10 mM. Ip was 
near maximal at 5.4 mM K
+
o. The 10 mM K
+
o-induced current was abolished by the washout of K
+
. The 
concentration-response relationship for the effect of K
+
o on Ip was examined in cells from 9 patients in SR. In 
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each cell, Ip density was fitted iteratively to logarithmic [K
+
]o with a variable slope sigmoidal curve, using 
the Hill equation: Y=Emin+[Emax-Emin]/[1+(x/EC50)
P
], where Y=Ip density (pA/pF), Emin=Ip at 0 mM (set to 0 
pA/pF), Emax=maximum Ip response elicitable by K
+
o (pA/pF), x=[K
+
]o (mM), EC50=[K
+
]o producing 50% of 
Emax (mM) and P=Hill coefficient. Fig 5A (open circles) shows the mean Ip density recorded at each [K
+
]o on 
a linear scale, with a single hyperbolic curve fitted to these data points using the same procedure as for the 
individual cells. The mean Emax and EC50, calculated from the individual cells’ curves, were 1.19±0.09 pA/pF 
and 1.71±0.15 mM, respectively (n=27 cells). 
 
Atrial fibrillation was not associated with a significant alteration of Ip [K
+
]o- or voltage-sensitivity 
 The [K
+
]o-dependency of Ip was examined in 9 patients who were in chronic AF, and compared with 
that of cells from the 9 patients in SR. Fig 5A (filled circles) shows the mean Ip density at different [K
+
]o (0-
10 mM) in the cells from patients in AF, with a single hyperbolic curve fitted, using the Hill equation, to the 
mean data points. The Ip [K
+
]o-response in cells from the patients in AF was similar to that in cells from the 
patients in SR (Fig 5A, open circles). The mean Ip at 5.4 and 10 mM K
+
o was not significantly different in the 
cells from patients in SR, at 0.97±0.06 and 1.05±0.08 pA/pF, respectively (n=27 cells) from those in the cells 
from patients in AF, at 0.85±0.04 and 0.91±0.05 pA/pF, respectively (P>0.05 for each; n=44 cells). 
Furthermore, the mean EC50 and Emax values were not significantly different in the patients in chronic AF (at 
1.54±0.11 mM and 1.02±0.05 pA/pF, respectively) from those measured in the patients in SR, as shown in 
Fig 5B. The 5.4 mM K
+
o-induced Ip steady-state I-V relationship was examined in cells from 8 patients in 
chronic AF, and compared with that obtained in cells from 9 patients in SR, as shown in Fig 5C. There was 
no significant difference in the voltage-dependency of Ip between the two patient groups, with both 
displaying an approximately linear increase in Ip with increasing voltage. 
 
Long-term digoxin therapy in patients with AF was associated with a small reduction in Ip 
 Sixty percent of the patients who were in chronic AF were treated pre-operatively with digoxin, versus 
none of the patients in SR (Table 1) (P<0.05, χ
2
 test). Since digoxin therapy may be expected to reduce Ip in 
human atrial tissues [23], the group of patients in chronic AF was sub-divided into those who were treated 
with digoxin and those who were not. The [K
+
]o-dependency of the atrial cell Ip was compared between these 
sub-groups, with the mean Ip values and [K
+
]o-response curves shown in Fig 6Ai, and the mean EC50 and 
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Emax in Fig 6Aii. Digoxin therapy was associated with a small, but significant, reduction in mean Emax, by 
19%, from 1.13±0.08 pA/pF (n=23 cells, 5 patients) to 0.92±0.07 pA/pF (P<0.05; n=21 cells, 4 patients). 
Digoxin therapy was also associated with a small, but significant, reduction in the mean EC50, by 23%, from 
1.76±0.14 to 1.35±0.15 mM (P<0.05). The potential influence on Ip of angiotensin converting enzyme (ACE) 
inhibition was also examined, since Ip was increased in rabbits by captopril treatment [24]. In cells from 
patients treated with ACE inhibitors, the Ip [K
+
]o-response Emax and EC50 were 1.29±0.11 pA/pF and 
1.98±0.25 mM, respectively (n=11 cells, 4 patients), not significantly different from that in cells from non-
treated patients, at 1.12±0.13 pA/pF and 1.51±0.17 mM, respectively (n=16 cells, 5 patients; P>0.05 for 
each).  
 
Atrial Ip was similar in the non-digoxin-treated patients in AF to that of the patients in SR 
  The concentration-response relationship for the effect of K
+
o on Ip was compared in cells from the 
patients who were in chronic AF but not treated with digoxin, to that obtained in cells from those patients in 
SR, none of whom were taking digoxin. Fig 6B shows that chronic AF, in the absence of the influence of 
digoxin therapy, was not associated with a significant change in the density or K
+
o-sensitivity of atrial Ip, 
with similar mean Ip [K
+
]o-response curves (Fig 6Bi) and similar mean EC50 and Emax values (Fig 6Bii) 
between the two patient groups. 
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Discussion 
 The Na, K pump current, Ip, was measured directly for the first time to our knowledge in human 
myocardium, and was shown to have similar characteristics to those recorded in several other species, 
including the responses to extracellular potassium, voltage and ouabain [3-7]. The half-maximal response to 
K
+
o was within the reported range (1.0-2.8 mM), and the Ip-voltage relationship was linear, in line with the 
majority of studies, although this may have been influenced by incomplete K
+
 current suppression, since Ip 
saturation was reported at 0 mV [6]. In addition, evidence has been provided, novel in any species, of a lack 
of change in atrial Ip associated with chronic AF, and also of a reduction in Ip associated with long-term 
digoxin therapy.  
 In cells from patients in chronic AF, Ip displayed a similar density, voltage- and [K
+
]o-sensitivity to that 
of cells from patients in SR, indicating that a change in neither the density nor functional properties of atrial 
Ip is involved in human AF-induced atrial electrophysiological remodelling. This is in line with the reported 
absence of change in atrial Na, K-ATPase activity following 2 hours of AF in sheep [16], and with the lack 
of effect of digoxin on atrial electrophysiological remodelling produced by 24 hours of AF in goats [17], 
although in the latter model, digoxin delayed the reversal of such remodelling [18]. However, the magnitude 
of Ip in-vivo may increase in patients during AF, since the rapid rate would increase the time spent in 
depolarisation. This may increase both [Na
+
]i and [K
+
]o, each of which increases Ip [3,4,6,7], as confirmed by 
the present data, which would contribute to the shortening of atrial APD and ERP during AF. However, Ip 
cannot be the major factor since atrial electrophysiological remodelling is observed in human atrial isolated 
cells even when the ionic concentrations are controlled [10-13,25]. 
 Long-term digoxin therapy was associated with a small reduction in atrial Ip. This was consistent with 
the reported reduction by digoxin therapy in the hyperpolarisation caused by rewarming of human atrial 
tissue considered due to reactivation of the Na,K pump following [Na
+
]i-loading [23]. The present magnitude 
of Ip reduction, of ~20%, corresponded with the reported percentage occupancy of digitalis receptors in 
chronically digitalised failing human ventricle, measured after protracted washing of tissues in anti-digoxin 
antibodies [26]. Alternatively, the observed reduction in Ip may represent an adaptive change analogous to 
the pharmacological remodelling of human atrial ion currents by chronic β-blockade [20]. Such a process 
would be consistent with the reduction in the number of Na, K-ATPase sites in HeLa cells exposed to 
ouabain [27]. It is not known whether the Ip reduction was influenced mainly by residual receptor occupancy 
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or by pharmacological remodelling. Since digoxin increased the sensitivity of Ip to K
+
o, an effect on the 
Na,K-ATPase α-2 isoform is a possibility, since its activity is strongly dependent on [K
+
]o [28]. Long-term 
ACE inhibition did not affect human atrial Ip, in agreement with the reported lack of effect on human atrial 
cell action potentials and ERP [20]. There have been no previous reports of effects of ACE inhibitors on 
human atrial Ip, although ventricular Ip was increased in captopril-treated rabbits, due to a reduction in 
interstitial and/or intracellular concentrations of angiotensin II, and not to a change in Na, K-ATPase 
expression [24].  
 A change in atrial Ip, whether by digoxin therapy as observed here, or by altered voltage and/or ionic 
conditions during AF in the absence of an electrophysiologically-remodelled Na,K pump would affect the 
APD and ERP, particularly with the high input resistance of human atrial cells [12,20]. Our results with 
ouabain suggested the potential for such an effect. It should be noted, however, that although ouabain 
completely blocked Ip and prolonged the APD and ERP in cells in-vitro, the degree of block in-vivo in 
patients treated with digoxin would be less (and possibly as low as the observed 19% reduction in Emax), and 
the consequent effect on the APD and ERP may also, therefore, be predicted to be less than that observed in-
vitro. No reports of effects of cardiac glycosides on action potentials in human atrial cells were found, but a 
small prolongation in atrial ERP was reported in patients administered ouabain [29] or digoxin [30]. 
However, acute digoxin had no effect on the ERP in goats [17,18] and APD-shortening by digitalis has also 
been reported [31,32]. In human atrial fibres [31], APD-shortening was secondary to vagal stimulation, but 
in guinea pig ventricular myocytes [32], it was due to a secondary ionic effect of Ip block, namely attenuation 
of the normally inward Na
+
/Ca
2+
 exchanger current (INa/Ca) by ouabain-induced [Na
+
]i-loading. The effects of 
digitalis on the APD and ERP in-vivo therefore result from a complex interaction between direct and 
secondary effects of Ip blockade and effects of vagal stimulation. It is also the case that the measurement of 
ERP that is made in single cells is not identical to that made in-vivo, since ERP is conventionally measured 
in terms of propagation failure, which cannot be measured in single cells. Nevertheless, action potentials of 
amplitude >80% of normal, as used here to define the cell ERP, have been shown to propagate, with graded 
responses occurring at lower amplitudes [21]. Additionally, 10 µM ouabain may affect action potentials via 
currents additional to Ip, such as ICaL [33]. However, since ICaL blockade with nifedipine had no effect on Vm 
or ERP in human atrial cells [12], this suggests that 10 µM ouabain largely affected these measurements by 
blocking Ip, supported by a mathematical model [5].  
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 Digoxin is used clinically as an inotropic drug to improve haemodynamic function, and also for 
ventricular rate control during AF, through central and peripheral augmentation of vagal tone to prolong the 
AV nodal ERP. Long-term digoxin treatment is positively inotropic by increasing [Ca
2+
]i, secondary to 
[Na
+
]i-loading by Ip blockade, although therapeutic serum concentrations (1-2 nM) are at least 50-fold lower 
than the minimum 0.1 µM required for acute Ip block [34]. [Na
+
]i-loading may contribute to APD-shortening 
in the atrium in-vivo, via a reduced INa/Ca, and [Ca
2+
]i-loading may also shorten the APD, via 
electrophysiological remodelling of ICaL and ITO [13]. Either or both of these influences on the APD may 
explain the reported delay by digoxin of recovery from AF-induced atrial electrophysiological remodelling in 
goats [18], and may also contribute to the lack of efficacy of digoxin in converting human AF [35]. Of note, 
in previous studies of human atrial cellular electrophysiological remodelling, the majority of patients in AF 
were taking digoxin [11,12,25]. However, any influence on the APD of [Na
+
]i-loading would have been 
removed by the controlled [Na
+
]i in each of these studies. Moreover, in the presence of residually-bound or 
down-regulated digoxin receptors, a reduction in the hyperpolarising and repolarising influences of Ip would 
contribute a direct APD-lengthening effect, as observed here with ouabain. Thus, the reported APD-
shortening associated with chronic AF in human atrial cells [11,12] may have been underestimated. 
 In conclusion, the present data indicate that chronic AF in humans, in the absence of the influence of 
digoxin therapy, was not associated with a significant change in the density of atrial Ip, or in its sensitivity to 
voltage or extracellular K
+
. 
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Tables and Fig legends 
 
Table 1. Patients’ characteristics. 
Values are numbers of patients (n and % of total, respectively) with selected clinical characteristics, except 
for age (mean±SE). CCB=calcium channel blocker, CABG=coronary artery bypass graft surgery, 
AVR=aortic valve replacement, MVR=mitral valve replacement, LV=left ventricular, MI=myocardial 
infarction. 
 
Table 2. Effects of ouabain on human atrial cell action potentials and refractory period. 
MDP=maximum diastolic potential; Vmax=action potential maximum upstroke velocity; APDx=action 
potential duration at x% repolarisation; ERP=effective refractory period. Values are means±SE (n=7 cells, 5 
patients, except for ERP: 5 cells, 4 patients). All patients were in SR. Stimulation rate=75 beats/min. 
Asterisks=P<0.05 vs control).  
 
Figure 1. 
Effects of ouabain on human atrial cell action potentials and refractoriness. 
Original action potential recordings from a single atrial cell from a patient in SR, in the absence () and 
presence () of ouabain (10 µM). A, Superimposed action potentials stimulated by the 7th of a train of 
conditioning current pulses, S1 (rate: 75 beats/min) showing the effects of ouabain on Vm and action potential 
configuration. B, Superimposed action potentials elicited, in the same cell, by the 7th and 8th S1 pulses, 
followed by responses to an increasingly premature test pulse, S2, showing the effects of ouabain on action 
potential restitution. The cell ERP (solid bars) was calculated as the longest S1-S2 interval failing to elicit an 
S2 response of amplitude >80% of the preceding S1 action potential. In each case, the S2 response used to 
measure this interval is labelled (
 
). 
 
Figure 2. 
Identification of human atrial Na, K pump current, Ip. 
Whole-cell current changes evoked by K
+
o and/or ouabain in atrial myocytes from patients in SR. Traces 
show A, activation of an outward current (I) by increasing [K
+
]o, current inhibition after decreasing [K
+
]o, 
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and abolition of K
+
o-induced current by ouabain; B, non-reversible and relatively slow abolition of Ip by 1 
µM ouabain. Bars show concentration and time-course of K
+
 and ouabain application. C, Histogram 
comparing mean K
+
o- and ouabain-sensitive current densities, calculated as peak K
+
o-induced current minus 
corresponding current in absence of K
+
o (
 
: n=17 cells, 4 patients) and in presence of ouabain at 1 µM (
 
: 
n=9 cells, 3 patients) and 10 µM (
 
: n=9 cells, 3 patients). All patients were in SR. Values are means±SE, 
NS=P>0.05 vs K
+
o-sensitive current. 
 
Figure 3. 
Voltage-dependency of human atrial Ip. 
Current-voltage (I-V) relationships for A, steady-state K
+
o-sensitive currents (n=17 cells, 9 patients); B, 
pseudo steady-state K
+
o-sensitive currents (n=25 cells, 12 patients); C, pseudo steady-state ouabain-sensitive 
currents (n=4 cells, 2 patients) in atrial cells from patients in SR. Upper panels (i) show representative 
whole-cell current traces and lower panels (ii) mean±SE I-V relationships at baseline (
 
), in the presence of 
5.4 mM K
+
o ( ) and following either washout of K
+
 (
 
) or addition of 10 µM ouabain ( ), with digital 
subtraction of baseline currents from those recorded in the presence of K
+ 
and ouabain indicated by   and 
 , respectively. 
 
Figure 4. 
Extracellular [K
+
]o-sensitivity of human atrial Ip. 
Original recording of whole cell current at a holding potential of -40 mV in a cell from a patient in SR, 
showing the effects on Ip amplitude of stepwise increments in [K
+
]o between 0 and 10 mM. 
 
Figure 5. 
Comparison of atrial Ip characteristics between patients in SR and chronic AF. 
Ip [K
+
]o-response curves (A) and characteristics (B) in cells from patients in SR (open symbols; n=27 cells, 9 
patients) and chronic AF (filled symbols; n=44 cells, 9 patients). Ip is expressed relative to that at 0 mM K
+
o. 
Mean data points were fitted by the Hill equation (see Results). Mean Emax (maximal Ip response to K
+
o) and 
EC50 ([K
+
]o producing 50% of Emax) were calculated from the individual cell curve-fit data. NS=P>0.05 
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between patient groups. C, Steady-state Ip I-V relationship in cells from patients in SR (
 
: n=17 cells, 9 
patients) and chronic AF (
 
: n=24 cells, 8 patients). All values are means±SE. 
 
Figure 6. 
Effects of digoxin therapy on atrial Ip, and comparison between non-digoxin-treated patients in SR and AF 
A, Comparison of the Ip [K
+
]o-response between cells from patients in chronic AF treated and not treated 
with digoxin. B, Comparison of the Ip [K
+
]o-response between patients in AF not treated with digoxin and 
those in SR. Concentration-response curves (i) and characteristics (ii) are shown. Values are means±SE.   
and 
 
=AF, not treated with digoxin (n=21 cells, 4 patients);   and 
 
=AF, treated with digoxin (n=23 cells, 
5 patients); open symbols=SR (n=27 cells, 9 patients). Asterisks=P<0.05 and NS=P>0.05 between patient 
sub-groups. 
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Table 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 
 
 
 
 
 
 
 
 
 
 
 
 
  Sinus 
rhythm 
Atrial 
fibrillation 
  n % n % 
Patient details 
 
Male/female 
Age (years) 
7/8 
60±3 
47/53 
- 
6/4 
65±3 
60/40 
- 
Drug treatments Lipid lowering 12 80 5 50 
 β-blocker 10 67 5 50 
 Nitrate 12 80 3 30 
 CCB 7 47 3 30 
 ACE inhibitor 7 47 6 60 
 Diuretic 5 33 6 70 
 Digoxin 0 0 6 60 
Operation type CABG 13 87 4 40 
 AVR 2 13 1 10 
 MVR 0 0 3 30 
 CABG + MVR 0 0 2 20 
LV function Normal 7 47 5 50 
 Mild/moderate 8 53 2 20 
 Severe 0 0 3 30 
Disease Angina 15 100 6 60 
 Hyperlipidaemia 12 80 4 40 
 Hypertension 7 47 2 20 
 Previous MI 8 53 3 30 
 Diabetes 2 13 1 10 
 Control Ouabain 
(10 µM) 
MDP (mV) -80 ± 2 -73 ± 2 * 
Vmax (V/s) 171 ± 16 72 ± 15 * 
Overshoot (mV) 47 ± 4 11 ± 5 * 
Amplitude (mV) 127 ± 6 84 ± 6 * 
APD50 (ms) 10.1 ± 1.6 19.9 ± 4.1 * 
APD75 (ms) 80 ± 7 101 ± 10 * 
APD90 (ms) 174 ± 17 197 ± 23 * 
ERP (ms) 198 ± 22 266 ± 14 * 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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